STOCK TITAN

Cresco Labs Stock Price, News & Analysis

CRLBF OTC Link

Company Description

Cresco Labs Inc. (CSE: CL, OTCQX: CRLBF, FSE: 6CQ) is a cannabis company that focuses on cultivation, production and branded product distribution, alongside operating retail dispensaries under the Sunnyside name. The company describes its mission as working to normalize and professionalize the cannabis and medical marijuana industry through a consumer packaged goods (CPG) approach to building national brands and a customer-focused retail experience.

Business focus and operating model

Cresco Labs positions itself as a leader in cultivation, production and branded product distribution of cannabis. According to its public statements, it leverages its scale and agility to grow a portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi on a national level. These brands are used to reach different segments of the regulated cannabis market through a CPG-style strategy.

On the retail side, Cresco Labs operates dispensaries nationally under the Sunnyside brand. The company states that these dispensaries are designed to build patient and consumer trust and to deliver an approachable, educational retail experience. Sunnyside locations offer cannabis products from Cresco Labs’ brand portfolio, and in some cases a curated selection of accessories, to qualifying patients and consumers in regulated markets.

Geographic footprint and market activity

Cresco Labs reports activity across multiple U.S. states and in at least one European market. In the United States, the company highlights operations in large regulated cannabis markets, including a medical marijuana presence in Florida and dispensaries in Ohio. For example, Cresco Labs has announced the opening of Sunnyside Tamarac in Florida and Sunnyside Proctorville in Ohio, describing these as part of a broader national Sunnyside footprint.

Beyond the U.S., Cresco Labs has disclosed the launch of Cresco-branded flower in Germany, marking its first commercial entry into the European Union. The company has stated that this launch is intended to pilot its brand in Germany’s regulated cannabis market and to gather insights that may inform future international expansion decisions.

Brands and retail platform

The company emphasizes a portfolio of national cannabis brands that it seeks to distribute widely through both wholesale and its own retail network. The brands specifically cited in its disclosures are:

  • Cresco
  • High Supply
  • FloraCal
  • Good News
  • Wonder Wellness Co.
  • Mindy’s
  • Remedi

Cresco Labs states that it operates highly productive dispensaries under the Sunnyside brand. These stores are described as focusing on education, convenience and a traditional retail experience, with an emphasis on building trust with patients and consumers in regulated cannabis programs.

Regulatory and capital markets profile

Cresco Labs is a reporting issuer in Canada and the United States and files with the U.S. Securities and Exchange Commission as a foreign private issuer on Form 40-F. The company has filed several Form 6-K reports that include unaudited condensed interim consolidated financial statements, management’s discussion and analysis, and material agreements such as a senior secured term loan agreement. These filings provide details on its financial condition, operating results and financing arrangements.

The company has disclosed a senior secured term loan and a refinancing of its senior secured credit facility. In its public communications, Cresco Labs has highlighted the refinancing of a senior secured term loan that extends maturity, reduces total debt compared to the prior facility and includes provisions for potential prepayment. It has described this refinancing as part of a disciplined approach to capital management and as a way to strengthen its balance sheet.

Corporate governance and shareholder matters

Cresco Labs holds an annual general and special meeting of shareholders where matters such as the election of directors and the appointment of auditors are voted on. The company has reported that shareholders approved the size of its board, elected directors and appointed Baker Tilly US, LLP as auditor for an ensuing year. It has also described an Award Exchange Program that allows certain employees to exchange underwater options for full value awards with new vesting terms, with the aim of linking pay to performance and retaining personnel.

Industry role and policy engagement

Cresco Labs repeatedly states that it aims to act as a steward for the cannabis industry on legislative and regulatory-focused initiatives. The company highlights year-round policy work, community outreach and its SEED initiative, which it describes as supporting communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives. These efforts are framed as part of its goal to help create what it calls a responsible, respectable and robust cannabis or medical marijuana industry.

The company has also publicly commented on major regulatory developments affecting cannabis in the United States. For example, Cresco Labs has issued statements regarding the federal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, characterizing this change as a significant moment for the regulated cannabis industry and noting potential implications for taxation, research and access to capital markets.

Financial reporting and performance communication

Cresco Labs provides regular updates on its financial and operating results through news releases and accompanying filings. These communications include revenue, gross profit, net income or loss, and non-GAAP measures such as EBITDA, Adjusted EBITDA, Adjusted gross profit and related margins. The company explains how it defines these non-GAAP measures and provides reconciliations to the most directly comparable U.S. GAAP measures in its financial disclosures.

In its commentary around quarterly results, Cresco Labs has discussed topics such as maintaining share positions in certain markets, refinancing debt, and pursuing growth opportunities in U.S. states and international markets. It links these financial updates to its broader strategy of operating a focused footprint, managing capital prudently and seeking opportunities in evolving cannabis markets.

Community engagement and SEED initiative

Through its public statements, Cresco Labs underscores community engagement as a core part of its identity. The company refers to its SEED initiative and other outreach efforts as vehicles for supporting economic opportunity, workforce development and investment in the communities where it operates. These initiatives are presented as aligned with its mission to help shape a cannabis industry that is responsible and respectable, with attention to social and legislative dimensions.

Stock and investor information

Cresco Labs’ subordinate voting shares trade on the Canadian Securities Exchange (CSE) under the symbol CL, and the company is quoted on the OTCQX market under the symbol CRLBF. It is also listed on the Frankfurt Stock Exchange under the symbol 6CQ. Investors can review its financial statements, management’s discussion and analysis and other disclosures through its filings on SEDAR+ and EDGAR, as referenced in its news releases and Form 6-K filings.

Stock Performance

$0.9100
-9.90%
0.10
Last updated: March 20, 2026 at 15:59
+24.38%
Performance 1 year
$363.1M

Cresco Labs (CRLBF) stock last traded at $0.9100, down 9.90% from the previous close. Over the past 12 months, the stock has gained 24.4%. At a market capitalization of $363.1M, CRLBF is classified as a small-cap stock with approximately 343.2M shares outstanding.

Latest News

Cresco Labs has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include earnings, earnings date, offering, conferences. View all CRLBF news →

SEC Filings

Cresco Labs has filed 5 recent SEC filings, including 3 Form 6-K, 1 Form 40-F, 1 Form SC TO-I/A. The most recent filing was submitted on March 5, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CRLBF SEC filings →

Financial Highlights

$655.8M
Revenue (TTM)
-$135.4M
Net Income (TTM)
$72.9M
Operating Cash Flow

Cresco Labs generated $655.8M in revenue over the trailing twelve months, retaining a 49.5% gross margin, operating income reached -$28.0M (-4.3% operating margin), and net income was -$135.4M, reflecting a -20.6% net profit margin. Diluted earnings per share stood at $-0.38. The company generated $72.9M in operating cash flow. With a current ratio of 2.59, the balance sheet reflects a strong liquidity position.

Upcoming Events

AUG
13
August 13, 2030 Financial

Term loan maturity

Senior secured term loan refinanced on maturity date

Cresco Labs has 1 upcoming scheduled event. The next event, "Term loan maturity", is scheduled for August 13, 2030 (in 1606 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the CRLBF stock price.

Short Interest History

Last 12 Months

Short interest in Cresco Labs (CRLBF) currently stands at 36.6 thousand shares, up 677.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 95.7%. This relatively low short interest suggests limited bearish sentiment.

Days to Cover History

Last 12 Months

Days to cover for Cresco Labs (CRLBF) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.

CRLBF Company Profile & Sector Positioning

Cresco Labs (CRLBF) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.

Investors comparing CRLBF often look at related companies in the same sector, including Verano Hldgs (VRNOF), Vireo Growth Inc (VREOF), Glass House Brands Inc (GLASF), Nika Pharmaceuticals (NIKA), and Elite Pharmaceuticals Inc (ELTP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CRLBF's relative position within its industry.

Frequently Asked Questions

What is the current stock price of Cresco Labs (CRLBF)?

The current stock price of Cresco Labs (CRLBF) is $0.91 as of March 20, 2026.

What is the market cap of Cresco Labs (CRLBF)?

The market cap of Cresco Labs (CRLBF) is approximately 363.1M. Learn more about what market capitalization means .

What is the revenue (TTM) of Cresco Labs (CRLBF) stock?

The trailing twelve months (TTM) revenue of Cresco Labs (CRLBF) is $655.8M.

What is the net income of Cresco Labs (CRLBF)?

The trailing twelve months (TTM) net income of Cresco Labs (CRLBF) is -$135.4M.

What is the earnings per share (EPS) of Cresco Labs (CRLBF)?

The diluted earnings per share (EPS) of Cresco Labs (CRLBF) is $-0.38 on a trailing twelve months (TTM) basis. Learn more about EPS .

What is the operating cash flow of Cresco Labs (CRLBF)?

The operating cash flow of Cresco Labs (CRLBF) is $72.9M. Learn about cash flow.

What is the profit margin of Cresco Labs (CRLBF)?

The net profit margin of Cresco Labs (CRLBF) is -20.6%. Learn about profit margins.

What is the operating margin of Cresco Labs (CRLBF)?

The operating profit margin of Cresco Labs (CRLBF) is -4.3%. Learn about operating margins.

What is the gross margin of Cresco Labs (CRLBF)?

The gross profit margin of Cresco Labs (CRLBF) is 49.5%. Learn about gross margins.

What is the current ratio of Cresco Labs (CRLBF)?

The current ratio of Cresco Labs (CRLBF) is 2.59, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the gross profit of Cresco Labs (CRLBF)?

The gross profit of Cresco Labs (CRLBF) is $324.6M on a trailing twelve months (TTM) basis.

What is the operating income of Cresco Labs (CRLBF)?

The operating income of Cresco Labs (CRLBF) is -$28.0M. Learn about operating income.

What does Cresco Labs Inc. do?

Cresco Labs Inc. focuses on cannabis cultivation, production and branded product distribution, and operates retail dispensaries under the Sunnyside brand. The company describes its mission as normalizing and professionalizing the cannabis and medical marijuana industry through a CPG approach to national brands and a customer-focused retail experience.

Which cannabis brands are associated with Cresco Labs?

Cresco Labs states that its portfolio includes the Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi brands. These brands are positioned as part of its national CPG-style strategy in regulated cannabis markets.

What is Sunnyside in relation to Cresco Labs?

Sunnyside is the retail dispensary brand operated by Cresco Labs. The company describes Sunnyside dispensaries as highly productive locations that focus on building patient and consumer trust and providing an educational, convenient and traditional retail experience in regulated cannabis markets.

On which exchanges does Cresco Labs trade?

Cresco Labs’ subordinate voting shares trade on the Canadian Securities Exchange under the symbol CL. The company is also quoted on the OTCQX market under the symbol CRLBF and on the Frankfurt Stock Exchange under the symbol 6CQ, as referenced in its public news releases.

How does Cresco Labs describe its role in cannabis industry policy?

Cresco Labs states that it acts as a steward for the cannabis industry on legislative and regulatory-focused initiatives. It highlights year-round policy work, community outreach and its SEED initiative as ways it supports communities through engagement, economic opportunity, investment, workforce development and legislative efforts.

Does Cresco Labs operate outside the United States?

Yes. Cresco Labs has announced the launch of Cresco-branded flower in Germany, which it describes as its first commercial entry into the European Union. The company presents this as part of an expanded growth strategy that pilots new investment platforms beyond U.S. cannabis.

What is Cresco Labs’ SEED initiative?

In its public statements, Cresco Labs refers to SEED as part of its community outreach and policy work. Through SEED and related efforts, the company says it supports communities via authentic engagement, economic opportunity, investment, workforce development and legislative initiatives tied to the cannabis industry.

How does Cresco Labs communicate its financial performance?

Cresco Labs releases quarterly financial and operating results through news releases and accompanying filings on SEDAR+ and EDGAR. These communications include U.S. GAAP financial information and non-GAAP measures such as EBITDA, Adjusted EBITDA, Adjusted gross profit and related margins, along with reconciliations and management discussion and analysis.

What type of SEC filer is Cresco Labs?

Cresco Labs files with the U.S. Securities and Exchange Commission as a foreign private issuer and uses Form 40-F for its annual reporting. It also files Form 6-K current reports that include interim financial statements, management’s discussion and analysis and material agreements such as senior secured term loan documentation.

How is Cresco Labs managing its debt and capital structure?

In its public disclosures, Cresco Labs has described refinancing its senior secured credit facility with a new senior secured term loan. The company states that this refinancing reduces total debt compared to the prior facility, extends maturity and provides flexibility for certain prepayments, which it characterizes as part of a disciplined approach to capital management.